ForPatients

by Roche

Rheumatoid Arthritis

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02251860 ML29087

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

ARATA is a prospective, non-interventional, multicenter, observational study in Germany to evaluate the long-term effectiveness and tolerability of subcutaneously administered tocilizumab in participants with rheumatoid arthritis in daily clinical practice. Participants will be followed over an observation period of up to 2 years after the initial injection.

Hoffmann-La Roche Sponsor		N/A Phase		
NCT02251860 ML29087 Trial Identifiers				
Eligibility Criteria:				
Gender All	Age >= 18 Years		Healthy Volunteers	